Thomson Reuters sells healthcare business for $1.25B

Thomson Reuters has entered into a definitive agreement to sell its healthcare business to an affiliate of Veritas Capital for $1.25 billion in cash.

This sale is a reversal of Thomson Reuters' January decision to shelve plans to sell its healthcare division "due to economic conditions."

This sale is subject to regulatory approval and customary closing conditions, including the expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to close in the next few months. The sale is not subject to any financing condition. Veritas has obtained debt financing commitments for the transaction.

The healthcare business provides data, analytics and performance benchmarking technologies and services to hospitals, health systems, employers, health plans, government agencies and healthcare professionals. Its assets include MarketScan, Advantage Suite, Micromedex, CareDiscovery and ActionOI.



Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.